Dr Robert Rifkin speaks to ecancer in an expert online interview for the virtual EHA 2020 meeting.
He begins by discussing the role of proteasome inhibitors in managing patients with multiple myeloma (MM) and the need for in-class transitioning in this patient population.
Dr Rifkin also gives an overview on the updated results from the community-based US MM-6 study, which is investigating long-term proteasome inhibition in MM following an in-class transition from bortezomib to ixazomib.
In light of these latest results (including updates in efficacy and safety), he explains the benefits of in-class transitioning from bortezomib to ixazomib and the implementation of this.
Dr Rifkin concludes by emphasising the importance of conducting community-based studies, and how this type of study can assist physicians in treating their patients; as the type of data gathered in these studies is more representative of the real world population.
This programme has been supported by an unrestricted educational grant from Takeda.